Aduro BioTech Inc (ADRO) EVP Sells $94,000.00 in Stock

Aduro BioTech Inc (NASDAQ:ADRO) EVP Dirk G. Brockstedt sold 10,000 shares of the company’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $9.40, for a total transaction of $94,000.00. Following the sale, the executive vice president now directly owns 77,674 shares of the company’s stock, valued at $730,135.60. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Shares of Aduro BioTech Inc (NASDAQ ADRO) traded down $0.40 during mid-day trading on Thursday, hitting $8.20. 658,800 shares of the stock were exchanged, compared to its average volume of 408,334. Aduro BioTech Inc has a 52 week low of $6.01 and a 52 week high of $14.05.

Aduro BioTech (NASDAQ:ADRO) last announced its earnings results on Tuesday, October 31st. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.03). The firm had revenue of $3.79 million for the quarter, compared to analyst estimates of $4.04 million. Aduro BioTech had a negative return on equity of 39.28% and a negative net margin of 548.92%. The company’s revenue for the quarter was up .0% compared to the same quarter last year. During the same quarter last year, the business earned ($0.54) EPS. sell-side analysts forecast that Aduro BioTech Inc will post -1.28 earnings per share for the current year.

ADRO has been the subject of a number of research reports. HC Wainwright set a $18.00 price target on shares of Aduro BioTech and gave the company a “buy” rating in a report on Wednesday, November 1st. Oppenheimer initiated coverage on shares of Aduro BioTech in a report on Monday, October 30th. They issued a “buy” rating and a $15.00 price target for the company. Finally, William Blair reissued an “outperform” rating on shares of Aduro BioTech in a report on Monday, October 2nd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $19.14.

Several institutional investors have recently made changes to their positions in ADRO. Harvard Management Co. Inc. acquired a new stake in Aduro BioTech in the 3rd quarter valued at about $69,418,000. Vanguard Group Inc. boosted its stake in shares of Aduro BioTech by 5.4% in the 2nd quarter. Vanguard Group Inc. now owns 2,511,995 shares of the biotechnology company’s stock valued at $28,637,000 after purchasing an additional 129,079 shares during the last quarter. State Street Corp boosted its stake in shares of Aduro BioTech by 8.3% in the 2nd quarter. State Street Corp now owns 684,699 shares of the biotechnology company’s stock valued at $7,808,000 after purchasing an additional 52,597 shares during the last quarter. Baillie Gifford & Co. boosted its stake in shares of Aduro BioTech by 30.8% in the 3rd quarter. Baillie Gifford & Co. now owns 553,090 shares of the biotechnology company’s stock valued at $5,891,000 after purchasing an additional 130,390 shares during the last quarter. Finally, Northern Trust Corp boosted its stake in shares of Aduro BioTech by 15.1% in the 2nd quarter. Northern Trust Corp now owns 453,115 shares of the biotechnology company’s stock valued at $5,166,000 after purchasing an additional 59,490 shares during the last quarter. Institutional investors and hedge funds own 45.19% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Aduro BioTech Inc (ADRO) EVP Sells $94,000.00 in Stock” was originally reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this report on another site, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this report can be viewed at https://www.chaffeybreeze.com/2017/12/07/aduro-biotech-inc-adro-evp-sells-94000-00-in-stock.html.

About Aduro BioTech

Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.

Insider Buying and Selling by Quarter for Aduro BioTech (NASDAQ:ADRO)

Receive News & Ratings for Aduro BioTech Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply